Form 10-Q Jasper Therapeutics, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Jasper Therapeutics (JSPR) PT Lowered to $68 at RBC Capital
August 14, 2024 6:25 AM EDTRBC Capital analyst Gregory Renza lowered the price target on Jasper Therapeutics (NASDAQ: JSPR) to $68.00 (from $70.00) while maintaining a Outperform rating.
The analyst comments "JSPR provided the updated timeline for briq's initial BEACON readout (CSU), now confirmed for 4Q24... More
